<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>484</ReferenceId>
        <DateLastUpdated>2020-09-10-07:00</DateLastUpdated>
        <Article>
            <PubmedId>15449035</PubmedId>
            <Abstract>Previous studies in small groups of patients suggested that immunization of melanoma patients with peptide epitopes recognized by T cells could induce regression of melanoma. This approach was tested in 36 patients with stage IV melanoma. The (MHC class I-restricted) peptides were from gp100, MART-1, tyrosinase, and MAGE-3. The gp100 and MART-1 peptides had been modified to increase their immunogenicity. In half the patients (groups 3 and 4) the peptides were given in the adjuvant Montanide-ISA-720, and half the patients in both groups were given GM-CSF s.c. for 4 days following each injection. Treatment was well tolerated except for two severe erythematous responses to Montanide-ISA-720 and marked inflammatory responses at sites of GM-CSF administration in three patients. There were no objective clinical responses but stabilization of disease for periods from 3 to 12 months were seen in seven patients. Five of these were patients given the peptides in Montanide-ISA-720. Delayed-type hypersensitivity (DTH) skin test responses were also seen mainly in the patients given the peptides in Montanide-ISA-720. GM-CSF did not increase DTH responses in patients in the latter group but may have increased DTH responses in those not given peptides in Montanide-ISA-720. Inflammatory responses around s.c. metastases or regional lymph nodes were observed in two patients. These results suggest that the peptides are more effective when given in the adjuvant Montanide-ISA-720. Nevertheless, results from this study, together with those from a number of comparable studies, indicate that peptide vaccines are currently of minimal benefit to patients and support the need for ongoing development of new strategies in treatment of this disease.</Abstract>
            <ArticleYear>2005</ArticleYear>
            <ArticlePages>208-18</ArticlePages>
            <ArticleTitle>Phase I/II study of immunotherapy with T-cell peptide epitopes in patients with stage IV melanoma.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Hersey</LastName>
                    <ForeName>Peter</ForeName>
                </Author>
                <Author>
                    <LastName>Menzies</LastName>
                    <ForeName>Scott W</ForeName>
                </Author>
                <Author>
                    <LastName>Coventry</LastName>
                    <ForeName>Brendon</ForeName>
                </Author>
                <Author>
                    <LastName>Nguyen</LastName>
                    <ForeName>Tam</ForeName>
                </Author>
                <Author>
                    <LastName>Farrelly</LastName>
                    <ForeName>Margaret</ForeName>
                </Author>
                <Author>
                    <LastName>Collins</LastName>
                    <ForeName>Susan</ForeName>
                </Author>
                <Author>
                    <LastName>Hirst</LastName>
                    <ForeName>Debbie</ForeName>
                </Author>
                <Author>
                    <LastName>Johnson</LastName>
                    <ForeName>Heather</ForeName>
                </Author>
            </Authors>
            <ArticleChemicalList>Antigens, Neoplasm;Cytokines;Epitopes;Epitopes, T-Lymphocyte;MAGEA3 protein, human;MART-1 Antigen;MLANA protein, human;Membrane Glycoproteins;Neoplasm Proteins;Oleic Acids;PMEL protein, human;Peptides;gp100 Melanoma Antigen;mannide monooleate;Mannitol;Interferon-gamma;Granulocyte-Macrophage Colony-Stimulating Factor;Monophenol Monooxygenase</ArticleChemicalList>
            <ArticleMeshHeadingsList>Adult; Aged; Aged, 80 and over; Antigens, Neoplasm(chemistry); Cytokines(metabolism); Enzyme-Linked Immunosorbent Assay; Epitopes(chemistry); Epitopes, T-Lymphocyte(chemistry); Female; Granulocyte-Macrophage Colony-Stimulating Factor(metabolism; pharmacology); Humans; Hypersensitivity, Delayed(immunology); Immunity, Cellular; Immunotherapy(methods); Inflammation; Interferon-gamma(metabolism); Lymphocytes(immunology); MART-1 Antigen; Male; Mannitol(analogs &amp; derivatives; pharmacology); Melanoma(immunology; therapy); Membrane Glycoproteins(chemistry); Middle Aged; Monophenol Monooxygenase(chemistry); Neoplasm Proteins(chemistry); Oleic Acids(pharmacology); Peptides(chemistry); Skin Neoplasms(immunology; therapy); Time Factors; Treatment Outcome; gp100 Melanoma Antigen</ArticleMeshHeadingsList>
            <Journal>
                <Volume>54</Volume>
                <Issue>3</Issue>
                <Title>Cancer immunology, immunotherapy : CII</Title>
                <Issn>1432-0851</Issn>
                <MedlineTa>Cancer Immunol Immunother</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>MAGE-3A.2</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>FLWGPRALV</LinearSequence>
                        <StartingPosition>271</StartingPosition>
                        <EndingPosition>279</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P43357.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>9606</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Page 209</LocationOfData>
                <EpitopeId>16970</EpitopeId>
                <ReferenceStartingPosition>271</ReferenceStartingPosition>
                <ReferenceEndingPosition>279</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 1</LocationOfData>
                        <TCellId>3158</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <MhcAlleleTypesPresent>
                                    <MhcAlleleId>235</MhcAlleleId>
                                </MhcAlleleTypesPresent>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of cancer</InVivoProcessType>
                                <DiseaseState>DOID:8923</DiseaseState>
                                <DiseaseStage>Chronic</DiseaseStage>
                                <DoseSchedule>The emulsified peptides were given subcutaneously over the lower abdomen or anterior thighs every 2 weeks for six vaccinations.</DoseSchedule>
                            </FirstInVivoProcess>
                            <SecondInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>FLWGPRALV</LinearSequence>
                                            <StartingPosition>271</StartingPosition>
                                            <EndingPosition>279</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P43357.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>9606</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>MAGE-3A.2</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Montanide ISA 720</Adjuvant>
                                <Route>Subcutaneous (s.c.)</Route>
                            </SecondInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                            </InVitroAdministration>
                            <ImmunizationComments>Patients were immunized with the HLA-A2-restricted peptides MAGE-3A.2, tyrosinase, gp100 209-2 M, gp100 280-9 V, and MART-1 26–35 as a cocktail.  In 2/3 patients who showed a positive IFN-γ response to the administration of this peptide, GM-CSF was also given subcutaneously near the site of peptide injections by constant infusion over 72 hours commencing at the time of peptide injection.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Short Term Restimulated</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>T2 cells-Lymphoblast</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                            <AutologousOrSyngeneic>N</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>235</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>MAGE-3A.2</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>FLWGPRALV</LinearSequence>
                                        <StartingPosition>271</StartingPosition>
                                        <EndingPosition>279</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P43357.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>73</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>36</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>3</NumberOfSubjectsResponded>
                            <ResponseFrequency>8.3</ResponseFrequency>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>MART-1 26-35 Analog</EpitopeName>
                <EpitopeStructure>
                    <SequenceMoleculeNoNaturalSource>
                        <ChemicalType>Peptide, no natural source</ChemicalType>
                        <LinearSequence>ELAGIGILTV</LinearSequence>
                    </SequenceMoleculeNoNaturalSource>
                </EpitopeStructure>
                <EpitopeRelatedObject>
                    <RelatedObjectType>The epitope is an analog of:</RelatedObjectType>
                    <RelatedObject>
                        <FragmentOfANaturalSequenceMolecule>
                            <ChemicalType>Peptide from protein</ChemicalType>
                            <LinearSequence>EAAGIGILTV</LinearSequence>
                            <StartingPosition>26</StartingPosition>
                            <EndingPosition>35</EndingPosition>
                            <SourceMolecule>
                                <GenBankId>Q16655.1</GenBankId>
                            </SourceMolecule>
                            <SourceOrganismId>9606</SourceOrganismId>
                        </FragmentOfANaturalSequenceMolecule>
                    </RelatedObject>
                </EpitopeRelatedObject>
                <LocationOfData>Page 209</LocationOfData>
                <EpitopeId>12941</EpitopeId>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>The MART-1 analog used in this study was made more immunogenic by modifying the native MART-1 26-35 epitope (EAAGIGILTV). This was done by replacing the anchor residue with an amino acid having higher binding affinities: i.e. L for A in position 2 of native MART-1 25-35.</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 1</LocationOfData>
                        <TCellId>3236</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <MhcAlleleTypesPresent>
                                    <MhcAlleleId>235</MhcAlleleId>
                                </MhcAlleleTypesPresent>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of cancer</InVivoProcessType>
                                <DiseaseState>DOID:8923</DiseaseState>
                                <DiseaseStage>Chronic</DiseaseStage>
                                <DoseSchedule>The emulsified peptides were given subcutaneously over the lower abdomen or anterior thighs every 2 weeks for six vaccinations.</DoseSchedule>
                            </FirstInVivoProcess>
                            <SecondInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <SequenceMoleculeNoNaturalSource>
                                            <ChemicalType>Peptide, no natural source</ChemicalType>
                                            <LinearSequence>ELAGIGILTV</LinearSequence>
                                        </SequenceMoleculeNoNaturalSource>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>MART-1 26-35 Analog</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Montanide ISA 720</Adjuvant>
                                <Route>Subcutaneous (s.c.)</Route>
                            </SecondInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                            </InVitroAdministration>
                            <ImmunizationComments>Patients were immunized with the HLA-A2-restricted peptides MAGE-3A.2, tyrosinase, gp100 209-2 M, gp100 280-9 V, and MART-1 26–35 as a cocktail.  In 2/3 patients who showed a positive IFN-γ response to the administration of this peptide, GM-CSF was also given subcutaneously near the site of peptide injections by constant infusion over 72 hours commencing at the time of peptide injection.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Short Term Restimulated</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>T2 cells-Lymphoblast</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                            <AutologousOrSyngeneic>N</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>235</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>MART-1 26-35 Analog</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <SequenceMoleculeNoNaturalSource>
                                        <ChemicalType>Peptide, no natural source</ChemicalType>
                                        <LinearSequence>ELAGIGILTV</LinearSequence>
                                    </SequenceMoleculeNoNaturalSource>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>73</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>36</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>3</NumberOfSubjectsResponded>
                            <ResponseFrequency>8.3</ResponseFrequency>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>Tyrosinase&lt;sub&gt;372-380&lt;/sub&gt;</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>YMDGTMSQV</LinearSequence>
                        <SourceMolecule>
                            <IedbAccession>SRC279957</IedbAccession>
                        </SourceMolecule>
                        <SourceOrganismId>9606</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Page 209</LocationOfData>
                <EpitopeId>75043</EpitopeId>
                <ReferenceStartingPosition>372</ReferenceStartingPosition>
                <ReferenceEndingPosition>380</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Internal Identifier-no external match available</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 1</LocationOfData>
                        <TCellId>3237</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <MhcAlleleTypesPresent>
                                    <MhcAlleleId>235</MhcAlleleId>
                                </MhcAlleleTypesPresent>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of cancer</InVivoProcessType>
                                <DiseaseState>DOID:8923</DiseaseState>
                                <DiseaseStage>Chronic</DiseaseStage>
                                <DoseSchedule>The emulsified peptides were given subcutaneously over the lower abdomen or anterior thighs every 2 weeks for six vaccinations.</DoseSchedule>
                            </FirstInVivoProcess>
                            <SecondInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>YMDGTMSQV</LinearSequence>
                                            <SourceMolecule>
                                                <IedbAccession>SRC279957</IedbAccession>
                                            </SourceMolecule>
                                            <SourceOrganismId>9606</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Tyrosinase&lt;sub&gt;372-380&lt;/sub&gt;</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Montanide ISA 720</Adjuvant>
                                <Route>Subcutaneous (s.c.)</Route>
                            </SecondInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                            </InVitroAdministration>
                            <ImmunizationComments>Patients were immunized with the HLA-A2-restricted peptides MAGE-3A.2, tyrosinase, gp100 209-2 M, gp100 280-9 V, and MART-1 26–35 as a cocktail.  In 2/3 patients who showed a positive IFN-γ response to the administration of this peptide, GM-CSF was also given subcutaneously near the site of peptide injections by constant infusion over 72 hours commencing at the time of peptide injection.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Short Term Restimulated</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>T2 cells-Lymphoblast</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                            <AutologousOrSyngeneic>N</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>235</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>Tyrosinase&lt;sub&gt;372-380&lt;/sub&gt;</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>YMDGTMSQV</LinearSequence>
                                        <SourceMolecule>
                                            <IedbAccession>SRC279957</IedbAccession>
                                        </SourceMolecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>73</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>36</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>3</NumberOfSubjectsResponded>
                            <ResponseFrequency>8.3</ResponseFrequency>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>GP100 280-9 V Analog</EpitopeName>
                <EpitopeStructure>
                    <SequenceMoleculeNoNaturalSource>
                        <ChemicalType>Peptide, no natural source</ChemicalType>
                        <LinearSequence>YLEPGPVTVP</LinearSequence>
                    </SequenceMoleculeNoNaturalSource>
                </EpitopeStructure>
                <LocationOfData>Page 209</LocationOfData>
                <EpitopeId>74642</EpitopeId>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>The gp100 analog used in this study was made more immunogenic by modifying the native gp100 epitope (YLEPGPVTAP). This was done by replacing the anchor residue with an amino acid having higher binding affinities: i.e. V for A in position 9 of native gp100.</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 1</LocationOfData>
                        <TCellId>3238</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <MhcAlleleTypesPresent>
                                    <MhcAlleleId>235</MhcAlleleId>
                                </MhcAlleleTypesPresent>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of cancer</InVivoProcessType>
                                <DiseaseState>DOID:8923</DiseaseState>
                                <DiseaseStage>Chronic</DiseaseStage>
                                <DoseSchedule>The emulsified peptides were given subcutaneously over the lower abdomen or anterior thighs each 2 weeks for six vaccinations.</DoseSchedule>
                            </FirstInVivoProcess>
                            <SecondInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <SequenceMoleculeNoNaturalSource>
                                            <ChemicalType>Peptide, no natural source</ChemicalType>
                                            <LinearSequence>YLEPGPVTVP</LinearSequence>
                                        </SequenceMoleculeNoNaturalSource>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>GP100 280-9 V Analog</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Montanide ISA 720</Adjuvant>
                                <Route>Subcutaneous (s.c.)</Route>
                            </SecondInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                            </InVitroAdministration>
                            <ImmunizationComments>Patients were immunized with the HLA-A2-restricted peptides MAGE-3A.2, tyrosinase, gp100 209-2 M, gp100 280-9 V, and MART-1 26–35 as a cocktail.  In 3/4 patients who showed a positive IFN-γ response to the administration of this peptide, GM-CSF was also given subcutaneously near the site of peptide injections by constant infusion over 72 hours commencing at the time of peptide injection.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Short Term Restimulated</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>T2 cells-Lymphoblast</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                            <AutologousOrSyngeneic>N</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>235</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>GP100 280-9 V Analog</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <SequenceMoleculeNoNaturalSource>
                                        <ChemicalType>Peptide, no natural source</ChemicalType>
                                        <LinearSequence>YLEPGPVTVP</LinearSequence>
                                    </SequenceMoleculeNoNaturalSource>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>73</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>36</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>4</NumberOfSubjectsResponded>
                            <ResponseFrequency>11.1</ResponseFrequency>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>GP100 209-2 M Analog</EpitopeName>
                <EpitopeStructure>
                    <SequenceMoleculeNoNaturalSource>
                        <ChemicalType>Peptide, no natural source</ChemicalType>
                        <LinearSequence>IMDQVPFSV</LinearSequence>
                    </SequenceMoleculeNoNaturalSource>
                </EpitopeStructure>
                <EpitopeRelatedObject>
                    <RelatedObjectType>The epitope is an analog of:</RelatedObjectType>
                    <RelatedObject>
                        <FragmentOfANaturalSequenceMolecule>
                            <ChemicalType>Peptide from protein</ChemicalType>
                            <LinearSequence>ITDQVPFSV</LinearSequence>
                            <StartingPosition>209</StartingPosition>
                            <EndingPosition>217</EndingPosition>
                            <SourceMolecule>
                                <GenBankId>P40967.2</GenBankId>
                            </SourceMolecule>
                            <SourceOrganismId>9606</SourceOrganismId>
                        </FragmentOfANaturalSequenceMolecule>
                    </RelatedObject>
                </EpitopeRelatedObject>
                <LocationOfData>Page 209</LocationOfData>
                <EpitopeId>27469</EpitopeId>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>The gp100 analog used in this study was made more immunogenic by modifying the native gp100 epitope (ITDQVPFSV). This was done by replacing the anchor residue with an amino acid having higher binding affinities: i.e. M for T at position 2 of native gp100.</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 1</LocationOfData>
                        <TCellId>3239</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <MhcAlleleTypesPresent>
                                    <MhcAlleleId>235</MhcAlleleId>
                                </MhcAlleleTypesPresent>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of cancer</InVivoProcessType>
                                <DiseaseState>DOID:8923</DiseaseState>
                                <DiseaseStage>Chronic</DiseaseStage>
                                <DoseSchedule>The emulsified peptides were given subcutaneously over the lower abdomen or anterior thighs every 2 weeks for six vaccinations.</DoseSchedule>
                            </FirstInVivoProcess>
                            <SecondInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <SequenceMoleculeNoNaturalSource>
                                            <ChemicalType>Peptide, no natural source</ChemicalType>
                                            <LinearSequence>IMDQVPFSV</LinearSequence>
                                        </SequenceMoleculeNoNaturalSource>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>GP100 209-2 M Analog</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Montanide ISA 720</Adjuvant>
                                <Route>Subcutaneous (s.c.)</Route>
                            </SecondInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                            </InVitroAdministration>
                            <ImmunizationComments>Patients were immunized with the HLA-A2-restricted peptides MAGE-3A.2, tyrosinase, gp100 209-2 M, gp100 280-9 V, and MART-1 26–35 as a cocktail.  In 3/4 patients who showed a positive IFN-γ response to the administration of this peptide, GM-CSF was also given subcutaneously near the site of peptide injections by constant infusion over 72 hours commencing at the time of peptide injection.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Short Term Restimulated</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>T2 cells-Lymphoblast</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                            <AutologousOrSyngeneic>N</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>235</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>GP100 209-2 M Analog</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <SequenceMoleculeNoNaturalSource>
                                        <ChemicalType>Peptide, no natural source</ChemicalType>
                                        <LinearSequence>IMDQVPFSV</LinearSequence>
                                    </SequenceMoleculeNoNaturalSource>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>73</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>36</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>4</NumberOfSubjectsResponded>
                            <ResponseFrequency>11.1</ResponseFrequency>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

